ARA-290 potentially reduces inflammation, alleviates neuropathic pain, and promotes tissue repair without increasing red blood cell production. It offers potential benefits for conditions like small fiber neuropathy and type 2 diabetes. ARA-290 is a synthetic peptide derived from erythropoietin (EPO). It selectively targets the innate repair receptor (IRR) to reduce inflammation, modulate neuropathic pain, and promote tissue repair. Unlike EPO, ARA-290 does not promote red blood cell production, making it a safer alternative for addressing inflammatory and neurodegenerative conditions. It selectively activates repair pathways, offering potential benefits for conditions like small fiber neuropathy and type 2 diabetes.
ARA-290
Also known as: Cibinetide; PH-BSP
Overview
Benefits
- Neuropathic pain relief
- Regulates blood sugar
- Protects neurons from oxidative stress
- May contribute to better lipid profiles
- Inflammation reduction
Consider This Peptide If You Want To
- Experience neuropathic pain or small fiber neuropathy and want relief without erythropoietin-related risks
- Reduce inflammation and promote tissue repair, e.g., in type 2 diabetes or chronic inflammatory disorders
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount: 4 mg
• Frequency: daily
• Duration: 4 weeks
• Rest Period: 4 weeks
• Time of Day: morning
• Ingestion: subcutaneous
Administration Routes:
- Subcutaneous
Research Findings on Dosage:
1. Subcutaneous Injection:
• Commonly Reported Dosage: 4 mg daily
• Note: ARA-290 is soluble in alkaline solutions and may appear cloudy when reconstituted with bacteriostatic water. This is normal and not an indication of a product quality issue.
• Duration: 30 days on, 30 days off
Mechanism of Action
How this peptide works in the body
Selective IRR Activation:
• ARA-290 binds to the innate repair receptor (IRR), a heterodimer of erythropoietin receptor (EPOR) and CD131, triggering the JAK2/STAT5 signaling pathway to regulate inflammation and cellular repair. This activation inhibits NF-κB, reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, leading to anti-inflammatory and cytoprotective effects.
Neuroprotection and Tissue Repair:
• By activating IRR, ARA-290 enhances PI3K/Akt signaling, which promotes cell survival, reduces oxidative stress, and prevents apoptosis in neurons and endothelial cells. It also upregulates BDNF and NGF, essential for nerve regeneration and synaptic plasticity, making it beneficial for small fiber neuropathy and diabetic neuropathy.
Non-Erythropoietic Activity:
• Unlike erythropoietin (EPO), ARA-290 does not bind to homodimeric EPOR receptors, thereby avoiding erythropoiesis (red blood cell production). This allows it to provide tissue-protective and anti-inflammatory effects without increasing hematocrit or thrombosis risk.
Consider Stacking With
- Any GHRP (Ipamorelin, Hexarelin)
- Any GHRH (CJC-1295, MOD-GRF-129, Tesamorelin)
- BPC-157
- TB-4
- TA-1
Side Effects & Cautions
Common Side Effects
- Mild injection site redness or irritation
Research & References
Research Highlights
1. Small Fiber Neuropathy:
• Study Population: Patients with sarcoidosis-associated neuropathy.
• Findings: ARA-290 improved symptoms and increased corneal nerve fiber density.
2. Metabolic Improvements:
• In patients with type 2 diabetes, ARA-290 reduced HbA1c and improved neuropathic symptoms.
3. Safety Profile:
• Well-tolerated in clinical trials with minimal side effects.
References
• Peptide Sciences Summary of ARA-290
• Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy (PubMed)
• ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (PubMed)
• ARA 290 Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes (PubMed)
• Small Fiber Neuropathy and ARA-290 Results (Video)